​

Recursion Pharmaceuticals Ownership | Who Owns Recursion Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

Recursion Pharmaceuticals Ownership Summary

Recursion Pharmaceuticals is owned by 102.50% institutional investors, 3.72% insiders. Vanguard group is the largest institutional shareholder, holding 12.04% of RXRX shares. ARK Innovation ETF is the top mutual fund, with 4.74% of its assets in Recursion Pharmaceuticals shares.

RXRX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockRecursion Pharmaceuticals102.50%3.72%-6.22%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group34.01M12.04%$229.91M
Ark investment management32.35M11.45%$218.66M
Baillie gifford24.86M8.80%$168.08M
Blackrock funding, inc. /de23.44M8.29%$158.43M
Blackrock17.31M7.33%$129.83M
Softbank group14.67M5.19%$99.15M
Mubadala investment co pjsc12.99M4.60%$87.78M
Kinnevik ab (publ)11.91M4.21%$80.48M
State street8.75M3.71%$65.62M
Novo10.11M3.58%$68.37M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kinnevik ab (publ)11.91M100.00%$80.48M
Dcvc opportunity fund ii gp3.95M23.64%$26.71B
Data collective iv gp5.94M17.75%$40.16B
Nvidia7.71M17.11%$52.10M
Mic capital management uk llp9.64M9.23%$65.19M
Novo10.11M4.14%$68.37M
Nan fung group664.61K3.84%$4.49M
Pivotal bioventure partners investment advisor595.52K2.72%$4.03M
Ark investment management32.35M1.82%$218.66M
Carroll investors246.99K0.94%$1.67M

Top Buyers

HolderShares% AssetsChange
Softbank group14.67M0.42%14.67M
Novo10.11M4.14%10.11M
Vanguard group34.01M0.00%9.74M
Blackrock17.31M0.00%4.99M
Norges bank3.47M0.00%3.47M

Top Sellers

HolderShares% AssetsChange
Ra capital management7.73M0.69%-7.66M
State street8.75M0.00%-1.60M
Platinum investment management395.67K0.12%-1.40M
Fmr7.07M0.00%-1.29M
Ghisallo capital management---1.10M

New Positions

HolderShares% AssetsChangeValue
Softbank group14.67M0.42%14.67M$99.15M
Novo10.11M4.14%10.11M$68.37M
Norges bank3.47M0.00%3.47M$23.43M
Nan fung group664.61K3.84%664.61K$4.49M
Pivotal bioventure partners investment advisor595.52K2.72%595.52K$4.03M

Sold Out

HolderChange
Nbc securities-1.00
Financial gravity asset management-4.00
Householder group estate & retirement specialist-11.00
Gradient investments-15.00
Ancora advisors-23.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202430810.79%289,638,35211.01%1021.20%18116.77%5612.00%
Sep 30, 2024275-1.43%260,863,9783.59%920.81%154-13.97%49-
Jun 30, 20242778.20%251,804,69520.07%1061.35%17712.74%49-5.77%
Mar 31, 202425625.49%209,712,7241.55%881.13%15738.94%5215.56%
Dec 31, 20232042.00%206,519,35235.69%881.76%113-14.39%4525.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Innovation ETF19.04M4.74%-182.44K
ARK Disruptive Innovation Full Composite18.28M4.68%450.11K
Scottish Mortgage Ord18.17M4.52%-
ARK Genomic Revolution ETF12.33M3.07%475.51K
ARK Genomic Revolution11.51M2.95%-1.20M
Vanguard Total Stock Mkt Idx Inv11.62M2.89%8.00K
Vanguard Small Cap Index9.26M2.30%7.55K
Vanguard US Total Market Shares ETF8.01M1.99%1.01M
SPDR® S&P Biotech ETF7.33M1.82%-78.54K
iShares Russell 2000 ETF6.62M1.65%-57.37K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 27, 2025Gibson Christopher Chief Executive OfficerSell$836.99K
Mar 05, 2025Gibson Christopher Chief Executive OfficerSell$131.60K
Mar 06, 2025Gibson Christopher Chief Executive OfficerSell$127.40K
Feb 05, 2025Gibson Christopher Chief Executive OfficerSell$153.60K
Feb 06, 2025Gibson Christopher Chief Executive OfficerSell$162.40K

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1-7
2024 Q4-15
2024 Q3-21
2024 Q2-22

RXRX Ownership FAQ

Who Owns Recursion Pharmaceuticals?

Recursion Pharmaceuticals shareholders are primarily institutional investors at 102.50%, followed by 3.72% insiders and -6.22% retail investors. The average institutional ownership in Recursion Pharmaceuticals's industry, Biotech Stocks , is 68.48%, which Recursion Pharmaceuticals exceeds.

Who owns the most shares of Recursion Pharmaceuticals?

Recursion Pharmaceuticals’s largest shareholders are Vanguard group (34.01M shares, 12.04%), Ark investment management (32.35M shares, 11.45%), and Baillie gifford (24.86M shares, 8.80%). Together, they hold 32.28% of Recursion Pharmaceuticals’s total shares outstanding.

Does Blackrock own Recursion Pharmaceuticals?

Yes, BlackRock owns 7.33% of Recursion Pharmaceuticals, totaling 17.31M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 129.83M$. In the last quarter, BlackRock increased its holdings by 4.99M shares, a 40.49% change.

Who is Recursion Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Kinnevik ab (publ) is Recursion Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 100.00% of its assets in 11.91M Recursion Pharmaceuticals shares, valued at 80.48M$.

Who is the top mutual fund holder of Recursion Pharmaceuticals shares?

ARK Innovation ETF is the top mutual fund holder of Recursion Pharmaceuticals shares, with 4.74% of its total shares outstanding invested in 19.04M Recursion Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools